The estimated Net Worth of Ted White is at least $2.52 Million dollars as of 26 August 2024. Mr. White owns over 34,000 units of Verrica Pharmaceuticals Inc stock worth over $416,816 and over the last 6 years he sold VRCA stock worth over $662,903. In addition, he makes $1,441,190 as President, Chief Executive Officer, and Director at Verrica Pharmaceuticals Inc.
Ted has made over 10 trades of the Verrica Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 34,000 units of VRCA stock worth $88,740 on 26 August 2024.
The largest trade he's ever made was selling 50,677 units of Verrica Pharmaceuticals Inc stock on 21 July 2023 worth over $244,770. On average, Ted trades about 11,575 units every 133 days since 2018. As of 26 August 2024 he still owns at least 215,967 units of Verrica Pharmaceuticals Inc stock.
You can see the complete history of Mr. White stock trades at the bottom of the page.
Ted W. White is President, Chief Executive Officer, Director of the Company. Previously, from 2011 to September 2017, Mr. White was the President and General Manager of Aqua Pharmaceuticals, an Almirall company. Prior to Aqua Pharmaceuticals, Mr. White was at Novartis from 1989 to 2010, where he served in a number of roles, most recently as a Managing Director. Mr. White holds a M.B.A. from St. Joseph’s University and a B.A. in General Arts from Villanova University. Our Board of Directors believes that Mr. White is qualified to serve as a director based on his role as our President and Chief Executive Officer and his extensive management experience in the pharmaceutical industry.
As the President, Chief Executive Officer, and Director of Verrica Pharmaceuticals Inc, the total compensation of Ted White at Verrica Pharmaceuticals Inc is $1,441,190. There are no executives at Verrica Pharmaceuticals Inc getting paid more.
Ted White is 55, he's been the President, Chief Executive Officer, and Director of Verrica Pharmaceuticals Inc since 2017. There are 7 older and 7 younger executives at Verrica Pharmaceuticals Inc. The oldest executive at Verrica Pharmaceuticals Inc is Lawrence Eichenfield, 62, who is the Director.
Ted's mailing address filed with the SEC is C/O VERRICA PHARMACEUTICALS INC., 44 WEST GAY STREET, SUITE 400, WEST CHESTER, PA, 19380.
Over the last 6 years, insiders at Verrica Pharmaceuticals Inc have traded over $8,200,904 worth of Verrica Pharmaceuticals Inc stock and bought 11,305,854 units worth $62,586,502 . The most active insiders traders include Advisors Llcperceptive Life..., Paul B Manning, and John A Iii Stalfort. On average, Verrica Pharmaceuticals Inc executives and independent directors trade stock every 20 days with the average trade being worth of $213,456. The most recent stock trade was executed by Christopher G. Hayes on 26 August 2024, trading 35,713 units of VRCA stock currently worth $93,211.
verrica pharmaceuticals inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the united states. the company's lead product candidate include vp-102 that is in phase iii clinical trial for the treatment of molluscum contagiosum; in phase ii clinical trial for the treatment of common warts; and completed phase i clinical trial for the treatment of genital warts. it is also developing cantharidin-based product candidate, vp-103 for the treatment of plantar warts. the company has a license agreement with lytix biopharma as to develop and commercialize ltx-315 for dermatologic oncology indications. verrica pharmaceuticals inc. was founded in 2013 and is headquartered in west chester, pennsylvania.
Verrica Pharmaceuticals Inc executives and other stock owners filed with the SEC include: